EAGLE PHARMACEUTICALS INC's ticker is EGRX and the CUSIP is 269796108. A total of 184 filers reported holding EAGLE PHARMACEUTICALS INC in Q2 2018. The put-call ratio across all filers is 1.00 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $351 | -42.4% | 22,262 | -28.9% | 0.02% | -38.7% |
| Q2 2023 | $609 | -11.7% | 31,292 | +28.8% | 0.03% | 0.0% |
| Q1 2023 | $690 | -2.7% | 24,304 | +0.1% | 0.03% | -8.8% |
| Q4 2022 | $709 | -99.9% | 24,273 | -0.9% | 0.03% | +9.7% |
| Q3 2022 | $646,000 | -40.7% | 24,489 | -0.1% | 0.03% | -35.4% |
| Q2 2022 | $1,090,000 | -29.3% | 24,516 | -21.3% | 0.05% | -21.3% |
| Q1 2022 | $1,542,000 | +22.9% | 31,146 | +26.3% | 0.06% | +56.4% |
| Q4 2021 | $1,255,000 | -12.1% | 24,661 | -3.6% | 0.04% | -15.2% |
| Q3 2021 | $1,428,000 | +208.4% | 25,579 | +136.6% | 0.05% | +206.7% |
| Q2 2021 | $463,000 | +2.9% | 10,813 | +0.2% | 0.02% | -6.2% |
| Q1 2021 | $450,000 | -66.8% | 10,788 | -63.0% | 0.02% | -65.2% |
| Q4 2020 | $1,356,000 | -29.0% | 29,128 | -35.3% | 0.05% | -27.0% |
| Q3 2020 | $1,911,000 | -14.3% | 44,997 | -3.2% | 0.06% | +3.3% |
| Q2 2020 | $2,229,000 | +6.0% | 46,461 | +1.7% | 0.06% | -3.2% |
| Q1 2020 | $2,102,000 | -21.9% | 45,681 | +2.0% | 0.06% | +1.6% |
| Q4 2019 | $2,690,000 | -26.3% | 44,776 | -30.6% | 0.06% | -24.4% |
| Q3 2019 | $3,649,000 | +0.1% | 64,513 | -1.5% | 0.08% | 0.0% |
| Q2 2019 | $3,647,000 | +41.4% | 65,513 | +28.2% | 0.08% | +57.7% |
| Q1 2019 | $2,579,000 | +19.0% | 51,086 | -5.1% | 0.05% | +10.6% |
| Q4 2018 | $2,167,000 | -21.5% | 53,806 | +35.1% | 0.05% | -4.1% |
| Q3 2018 | $2,762,000 | -9.7% | 39,835 | -1.5% | 0.05% | -7.5% |
| Q2 2018 | $3,060,000 | +354.7% | 40,450 | +143.4% | 0.05% | +165.0% |
| Q1 2016 | $673,000 | -52.6% | 16,619 | +3.8% | 0.02% | -50.0% |
| Q4 2015 | $1,419,000 | +16.7% | 16,003 | -2.6% | 0.04% | +8.1% |
| Q3 2015 | $1,216,000 | -26.7% | 16,424 | -19.9% | 0.04% | -24.5% |
| Q2 2015 | $1,658,000 | +360.6% | 20,517 | +138.6% | 0.05% | +345.5% |
| Q1 2015 | $360,000 | +76.5% | 8,600 | -34.4% | 0.01% | +57.1% |
| Q4 2014 | $204,000 | +25.9% | 13,100 | +2.3% | 0.01% | +16.7% |
| Q3 2014 | $162,000 | – | 12,800 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| ProQuest Associates IV LLC | 3,652,284 | $302,920,000 | 91.10% |
| Hudson Executive Capital LP | 1,901,200 | $157,686,000 | 21.62% |
| JW Asset Management, LLC | 525,755 | $43,606,000 | 9.08% |
| Cormorant Asset Management, LP | 200,000 | $16,588,000 | 2.41% |
| Park West Asset Management LLC | 488,128 | $40,485,000 | 2.36% |
| Opaleye Management Inc. | 50,000 | $4,147,000 | 2.06% |
| Ranger Investment Management | 283,954 | $23,551,000 | 1.71% |
| Pier Capital, LLC | 74,732 | $6,198,000 | 1.06% |
| Bellevue Group AG | 67,700 | $5,615,000 | 0.75% |
| Orbimed Advisors | 671,000 | $55,653,000 | 0.63% |